AstraZeneca PLC

Symbol: AZN

NASDAQ

64.6

USD

Market price today

  • 40.6882

    P/E Ratio

  • 1.2639

    PEG Ratio

  • 200.25B

    MRK Cap

  • 0.02%

    DIV Yield

AstraZeneca PLC (AZN) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.82%

Operating Profit Margin

0.18%

Net Profit Margin

0.13%

Return on Assets

0.06%

Return on Equity

0.16%

Return on Capital Employed

0.12%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO:Mr. Pascal Soriot D.V.M., M.B.A.
Full-time employees:83500
City:Cambridge
Address:1 Francis Crick Avenue
IPO:1993-05-12
CIK:0000901832

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

General Outlook

When we look at how much money they make before expenses, they keep 0.820% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.179%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.130%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.059% return, is a testament to AstraZeneca PLC's adeptness in optimizing resource deployment. AstraZeneca PLC's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.159%. Furthermore, the proficiency of AstraZeneca PLC in capital utilization is underscored by a remarkable 0.116% return on capital employed.

Stock Prices

AstraZeneca PLC's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $76.8, while its low point bottomed out at $75.96. This variance in figures offers investors a lucid insight into the roller-coaster ride that is AstraZeneca PLC's stock market.

Liquidity Ratios

Analyzing AZN liquidity ratios reveals its financial health of the firm. The current ratio of 82.03% gauges short-term asset coverage for liabilities. The quick ratio (63.56%) assesses immediate liquidity, while the cash ratio (19.12%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio82.03%
Quick Ratio63.56%
Cash Ratio19.12%

Profitability Ratios

AZN profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 15.06% underscores its earnings before tax deductions. The effective tax rate stands at 13.60%, revealing its tax efficiency. The net income per EBT, 86.32%, and the EBT per EBIT, 84.21%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 17.88%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin15.06%
Effective Tax Rate13.60%
Net Income per EBT86.32%
EBT per EBIT84.21%
EBIT per Revenue17.88%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.82, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding64
Days of Inventory Outstanding239
Operating Cycle347.42
Days of Payables Outstanding144
Cash Conversion Cycle203
Receivables Turnover3.38
Payables Turnover2.53
Inventory Turnover1.52
Fixed Asset Turnover4.36
Asset Turnover0.45

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 3.31, and free cash flow per share, 2.10, depict cash generation on a per-share basis. The cash per share value, 1.88, showcases liquidity position. A payout ratio of 0.75 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.23, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share3.31
Free Cash Flow per Share2.10
Cash per Share1.88
Payout Ratio0.75
Operating Cash Flow Sales Ratio0.23
Free Cash Flow to Operating Cash Flow Ratio0.63
Cash Flow Coverage Ratio0.36
Short Term Coverage Ratio1.92
Capital Expenditure Coverage Ratio2.74
Dividend Paid and Capex Coverage Ratio1.25
Dividend Payout Ratio0.02

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 28.31%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.73, we discern the balance between debt and equity financing. The long-term debt to capitalization, 37.24%, and total debt to capitalization, 42.24%, ratios shed light on its capital structure. An interest coverage of 5.13 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio28.31%
Debt Equity Ratio0.73
Long Term Debt to Capitalization37.24%
Total Debt to Capitalization42.24%
Interest Coverage5.13
Cash Flow to Debt Ratio0.36
Company Equity Multiplier2.58

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 14.66, provides a glimpse into top-line earnings distributed across each share. Net income per share, 1.91, reflects the portion of profit attributed to each share. The book value per share, 12.53, represents the net asset value distributed per share, while the tangible book value per share, -6.07, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share14.66
Net Income Per Share1.91
Book Value Per Share12.53
Tangible Book Value Per Share-6.07
Shareholders Equity Per Share12.53
Interest Debt Per Share9.67
Capex Per Share-1.21

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 3.29%, indicates top-line expansion, while the gross profit growth, 17.47%, reveals profitability trends. EBIT growth, 118.07%, and operating income growth, 118.07%, offer insights into operational profitability progression. The net income growth, 81.11%, showcases bottom-line expansion, and the EPS growth, 81.13%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth3.29%
Gross Profit Growth17.47%
EBIT Growth118.07%
Operating Income Growth118.07%
Net Income Growth81.11%
EPS Growth81.13%
EPS Diluted Growth80.19%
Weighted Average Shares Growth0.13%
Weighted Average Shares Diluted Growth0.13%
Dividends per Share Growth2.55%
Operating Cash Flow Growth5.48%
Free Cash Flow Growth-9.26%
10-Year Revenue Growth per Share42.82%
5-Year Revenue Growth per Share68.22%
3-Year Revenue Growth per Share44.68%
10-Year Operating CF Growth per Share12.05%
5-Year Operating CF Growth per Share220.52%
3-Year Operating CF Growth per Share81.20%
10-Year Net Income Growth per Share86.74%
5-Year Net Income Growth per Share124.15%
3-Year Net Income Growth per Share56.62%
10-Year Shareholders Equity Growth per Share35.10%
5-Year Shareholders Equity Growth per Share154.66%
3-Year Shareholders Equity Growth per Share110.62%
10-Year Dividend per Share Growth per Share3.78%
5-Year Dividend per Share Growth per Share4.33%
3-Year Dividend per Share Growth per Share5.45%
Receivables Growth36.57%
Inventory Growth15.43%
Asset Growth4.80%
Book Value per Share Growth5.55%
Debt Growth-2.09%
R&D Expense Growth12.02%
SGA Expenses Growth-3.87%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 233,183,400,000, captures the company's total value, considering both debt and equity. Income quality, 1.50, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 57.49%, indicates the value of non-physical assets, and capex to operating cash flow, -36.52%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value233,183,400,000
Income Quality1.50
Research and Development to Revenue23.87%
Intangibles to Total Assets57.49%
Capex to Operating Cash Flow-36.52%
Capex to Revenue-8.25%
Capex to Depreciation-76.57%
Graham Number23.18
Return on Tangible Assets13.85%
Graham Net Net-13.83
Working Capital-5,488,000,000
Tangible Asset Value-18,971,000,000
Net Current Asset Value-36,899,000,000
Invested Capital1
Average Receivables11,737,500,000
Average Payables11,153,500,000
Average Inventory5,061,500,000
Days Sales Outstanding108
Days Payables Outstanding144
Days of Inventory On Hand239
ROIC10.28%
ROE0.15%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 6.19, and the price to book ratio, 6.19, reflect the market's valuation relative to the company's book value. The price to sales ratio, 5.25, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 36.63, and price to operating cash flows, 23.42, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio6.19
Price to Book Ratio6.19
Price to Sales Ratio5.25
Price Cash Flow Ratio23.42
Price Earnings to Growth Ratio1.26
Enterprise Value Multiple17.23
Price Fair Value6.19
Price to Operating Cash Flow Ratio23.42
Price to Free Cash Flows Ratio36.63
Price to Tangible Book Ratio5.38
Enterprise Value to Sales5.09
Enterprise Value Over EBITDA16.76
EV to Operating Cash Flow22.54
Earnings Yield2.83%
Free Cash Flow Yield3.12%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of AstraZeneca PLC (AZN) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 40.688 in 2024.

What is the ticker symbol of AstraZeneca PLC stock?

The ticker symbol of AstraZeneca PLC stock is AZN.

What is company IPO date?

IPO date of AstraZeneca PLC is 1993-05-12.

What is company current share price?

Current share price is 64.600 USD.

What is stock market cap today?

The market cap of stock today is 200249019034.000.

What is PEG ratio in 2024?

The current 1.264 is 1.264 in 2024.

What is the number of employees in 2024?

In 2024 the company has 83500.